You are here: Industry Insights > Kintor

News List

Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China prnasia
July 28, 2021
Kintor Pharmaceutical Limited announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay prnasia
July 16, 2021
Kintor today announced that Paraguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
Kintor partners with Fosun to market Covid-19 therapy in India and Africa pharmaceutical-technology
July 15, 2021
Kintor Pharmaceutical has signed a licensing agreement with Shanghai Fosun Pharmaceutical Development to market its drug, proxalutamide, for Covid-19 in India and 28 African countries.
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne prnasia
July 14, 2021
Kintor Pharmaceutical Limited today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects.
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US prnasia
July 13, 2021
Kintor Pharmaceutical Limited announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase II clinical trial for androgenetic alopecia(AGA) to be conducted in the US.
Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's prnasia
May 20, 2021
On May 18, Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's phase III ...
Kintor, Visum Enter COVID-19 Manufacturing Partnership contractpharma
April 20, 2021
Kintor Pharmaceutical, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, has entered a partnership with Hainan Visum Pharmaceutical to expand proxalutamide manufacturing.
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide prnasia
April 19, 2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients ...
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China prnasia
April 16, 2021
Kintor Pharmaceutical Limited announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (tincture/gel) for the treatment of acne and androgenetic alopecia.
Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing prnasia
April 15, 2021
Kintor Pharmaceutical Limited recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited to expand proxalutamide manufacturing.

Previous page 1 2 Next page